Parkinson's disease (PD) is a debilitating neurodegenerative disorder affecting ϳ1% of the population aged Ͼ65. Although the motor symptoms of PD are well defined, PD has a significant nonmotor component, including neuropsychiatric symptoms (depression, anxiety, dementia, cognitive dysfunction), sleep disorders, autonomic dysfunction, gastrointestinal (GI) dysfunction, and pain (Chaudhuri and Schapira, 2009 ). The nonmotor component of PD is often under-recognized and undertreated and can have a serious impact on patient quality of life. Management of nonmotor symptoms therefore represents a serious unmet medical need in PD (Langston, 2006) . Importantly, nonmotor symptoms of PD occur not only in advanced disease, but also in early stages. Indeed, it is suggested that olfactory dysfunction, constipation, rapid eye movement (REM) sleep behavior disorder (RBD), and depression might precede the onset of motor symptoms by 5-10 years (Chaudhuri and Schapira, 2009) . Thus, nonmotor symptoms of PD may offer a means to identify individuals "at risk" of developing PD before onset of motor symptoms, as well as a means to follow disease progression (Marek and Jennings, 2009) .
Although loss of dopamine (DA) contributes to nonmotor symptoms in PD, disruption of other neurotransmitter systems is also likely to be involved. Degeneration has been observed in noradrenergic (NA) and serotoninergic (5-HT) nuclei in PD, in particular the locus ceruleus (LC) and raphe nucleus (Braak et al., 2003) . Indeed, both NA and 5-HT are implicated in the development of depression and sleep disorders that are observed in PD patients (Chaudhuri and Schapira, 2009) . Furthermore, positron emission tomography (PET) studies demonstrate clear deficits in both NA and 5-HT systems in PD patients, and these deficits correlate with development of nonmotor symptoms, particularly depression (Brooks, 2007) . Together, these data suggest that PD is not only a dopaminergic disorder, but also involves deficits in other monoamine systems (Langston, 2006) .
Classically, preclinical models of PD are generated using DA-selective neurotoxins, such as 6-hydroxydopamine (6-OHDA) or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which do not model deficits in other transmitter systems (Jenner, 2008) . More recently, the neurotoxin rotenone has been used to model PD in rodents. Rotenone induces a general neuronal toxicity, affecting multiple systems, suggested to be more reminiscent of atypical parkinsonism (Jenner, 2008) . Nonmotor phenotypes in neurotoxin-based models have not been extensively analyzed until recently, but increasing evidence suggests that nonmotor symptoms of PD are present in the 6-OHDA, MPTP, and rotenone models (Table 1) . Crucially, however, these models do not show progressive, age-dependent neurodegeneration, which is particularly relevant to the etiology of PD (Jenner, 2008) . Other animal models have been generated on the basis of genes identified in familial cases of PD, which mimic some aspects of PD, including some nonmotor symptoms (Table 1) . However, these are only partially successful in modeling the full neuropathological spectrum of the disease (Jenner, 2008) . Thus, as yet there are still no genuinely progressive models that faithfully reproduce the cardinal features of PD (Jenner, 2008) .
Within this context, Mooslehner et al. (2001) generated a mouse expressing 5% of normal levels of the vesicular monoamine transporter 2 (VMAT2), which regulates packaging of not only DA, but also NA and 5-HT into synaptic vesicles in neurons (Mooslehner et al., 2001) . Caudle et al. (2007) characterize this mouse as a potential model of PD (Caudle et al., 2007) . Indeed, VMAT2-deficient mice showed moderate, but progressive loss of the nigrostriatal dopamine system, ␣-synuclein accumulation, and locomotor deficits (Caudle et al., 2007) . In addition, VMAT2 deficiency resulted in substantial depletion of NA and 5-HT levels, allowing testing of whether these transmitter systems might underpin nonmotor symptoms in PD. The recent article by Taylor et al. (2009) in The Journal of Neuroscience demonstrates that indeed, VMAT2-deficient mice exhibit age-dependent phenotypes mimicking many of the nonmotor symptoms of PD (Taylor et al., 2009) . Taylor et al. (2009) first investigated the neurochemical deficits present in VMAT2-deficient mice. These animals showed substantial reductions in DA, NA, and 5-HT in the striatum, hippocampus, and cortex at 12-15 months of age, as well as increased metabolism of DA and 5-HT, compared with wild-type (WT) controls [Taylor et al. (2009) 
The authors next characterized the behavioral manifestations of these neurochemical alterations in VMAT2-deficient and WT mice at different ages, using a range of tasks including tests of olfactory discrimination, sleep latency, gastrointestinal function, and anxiety/depressive phenotypes. Interestingly, VMAT2-deficient mice displayed progressive deficits in olfactory function from 5 months of age, which was not due to a problem in general sensory perception [Taylor et al. (2009) , their Fig. 2, Fig. 4 ]. As in human PD, the authors report that this was not corrected by levodopa (L-DOPA) treatment. Consistent with previous reports in other rodent preclinical models of PD, VMAT2-deficient mice also displayed a moderate decrease in gastric emptying [Taylor et al. (2009), their Fig. 6 ]. Young (4-6 month) VMAT2-deficient mice demonstrated decreased latency to sleep, compared with WT mice, a difference that became markedly less apparent with aging [Taylor et al. (2009) , their Fig. 5] . Notably, VMAT2-deficient mice also displayed clear anxiety and depressive-like phenotypes. Interestingly, these were also age dependent depending on the behavioral test [Taylor et al. (2009) , their Fig. 7] . Indeed, young (4 -6 months) but not old (12-15 months) VMAT2-deficient mice displayed a clear anxiety phenotype in the elevated plus maze. This is similar to the effects observed on sleep latency in VMAT2-deficient mice, leading the authors to suggest this may be due to a premature development of symptoms associated with normal aging. This hypothesis is supported by data demonstrating that VMAT2-deficient mice show statistically significant decreases in sleep latency and significantly increased time in the closed arms of the elevated plus maze at 4 -6 months of age compared with age-matched controls, which is absent when older VMAT2-deficient mice (12-15 months) are compared with age-matched WT controls [Taylor et al. (2009) , their Fig. 5A, Fig. 7A ]. In addition, young (4 -6 months) VMAT2-deficient mice show significantly decreased latency to sleep compared with old (12-15 months) VMAT2-deficient mice [Taylor et al. (2009) , their Fig. 5A ]. In contrast, in the forced swim and tail suspension tests only old (12-15 months), but not young (4 -6 months) VMAT2-deficient mice display a clear depressive phenotype [Taylor et al. (2009), their Fig. 7] . These data suggest anxiety behavior precedes depressive behavior in these animals. These data are somewhat representative of the clinical situation, although anxiety and depression frequently coexist in PD patients, even in the early stages of the disease (Aarsland et al., 2009 ). However, the spectrum of neuropsychiatric symptoms widens appreciably with advancing disease (Chaudhuri and Schapira, 2009 ).
The significance of this work compared with neurotoxin-based models that replicate some nonmotor symptoms of PD (Table 1), is that VMAT2-deficient mice show age-dependent and progressive onset of symptoms, as well as neurodegeneration of the nigrostriatal system and ␣-synuclein pathology, thus more closely replicating the human disease (Caudle et al., 2007; Taylor et al., 2009 ). Importantly, some of the nonmotor phenotypes of VMAT2-deficient mice, including olfactory deficits, anxiety, and gastrointestinal abnormalities precede degenerative and motor behavioral changes in these animals, while others are manifest alongside motor symptoms, such as depression, as has been documented in PD patients (Chaudhuri and Schapira, 2009 ). In addition, this model provides robust evidence that deficits in NA and 5-HT, as well as DA, may be involved in the development of PD nonmotor symptoms (Langston, 2006) .
Importantly however, these mice do not allow identification of behavioral phenotypes related to deficits in individual monoamine neurotransmitter systems, since the data presented by Taylor et al. (2009) suggest that DA, 5-HT, and NA levels are equally affected by the global VMAT2 deficiency. Thus, the current study cannot distinguish whether individual monoamine neurotransmitter systems are important for the development of different nonmotor symptoms, or if a combined dysfunction is required. In addition, it is not clear at what age and in what brain regions the neurochemical deficits in DA, NA, and 5-HT are first present in VMAT2-deficient mice. Although data from the previous characterization of this model suggests alterations in DA metabolism are present from 6 months of age in VMAT2-deficient mice (Caudle et al., 2007) , it is not clear whether other monoamine systems are perturbed at this time. This information could be useful for identifying intrinsic compensatory mechanisms as symptoms progress in these animals.
In their discussion, Taylor et al. (2009) cite unpublished evidence that extranigral neurodegeneration occurs in VMAT2-deficient mice, including in the LC and raphe nucleus [Taylor et al. (2009), their Discussion] . A more extensive evaluation of these data would be valuable because it has been suggested that neurodegeneration in these nuclei precedes degeneration in the substantia nigra, and this may manifest clinically as nonmotor symptoms, including olfactory deficits (Braak et al., 2003) . Specifically, it will be important to determine whether age-dependent, progressive degeneration occurs in these nuclei before nigral degeneration in VMAT2-deficient animals, and if so, Intrastriatal 6-OHDA Not described Not described No (Tadaiesky et al., 2008) Yes (Branchi et al., 2008; Tadaiesky et al., 2008) Yes (Ferro et al., 2005; Tadaiesky et al., 2008) Yes (Tassorelli et al., 2007; Chudler and Lu, 2008) MPTP (systemic) Yes (Anderson et al., 2007) Yes (Monaca et al., 2004; Barraud et al., 2009) Yes (Prediger et al., 2009 ) Yes (Vucković et al., 2008 Yes (Reksidler et al., 2007; Prediger et al., 2009) Yes (Rosland et al., 1992) Rotenone (systemic) Yes (Drolet et al., 2009; Greene et al., 2009) Not described Not described Not described Not described Not described ␣-synuclein TG (PARK1, PARK4)
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Parkin TG (PARK2) Not described Not described Not described Yes (Zhu et al., 2007) Yes (Zhu et al., 2007) Not described Vernon • Journal Clubwhether such changes underlie nonmotor symptoms that are present before the onset of nigral degeneration. Furthermore, it would be informative to correlate changes in behavior with evolution of ␣-synuclein pathology in the brains of VMAT2-deficient mice, because the onset of nonmotor symptoms is suggested to correlate with the progression of Lewy body (LB) pathology in PD (Braak et al., 2003) . Finally, other nonmotor characteristics of PD have not yet been explored in VMAT2-deficient mice. For example, cognitive dysfunction is a common feature of advanced PD, but may also be present before the onset of motor symptoms (WilliamsGray et al., 2007) . It may therefore be interesting to examine whether VMAT2-deficient mice display age-dependent cognitive deficits in behavioral paradigms such as the delayed matching to sample test using a T-maze. It is also not known whether VMAT2-deficient mice also display altered nociception or pain sensitivity. Importantly, DA can modulate pain in several CNS regions and unexplained or chronic pains are a significant component of the nonmotor complex of PD (Chaudhuri and Schapira, 2009 ). In addition, although the authors demonstrate that anxiety and depressive behavior in VMAT2-deficient animals were sensitive to antidepressant medication, it may be interesting to test whether these phenotypes are also sensitive to DA medication, as suggested in a human clinical trial (Chaudhuri and Schapira, 2009) . Nevertheless, this model, subject to further validation, may be a useful platform in which to evaluate the effects of DA and non-DA therapeutics on nonmotor symptoms of PD (Chaudhuri and Schapira, 2009 ). In addition, this model may offer a unique window of opportunity during which nonmotor symptoms and compensatory changes are present before the onset of motor symptoms and nigral neurodegeneration, in which to serially investigate biochemical, inflammatory, neuroimaging, and pathological changes in the brains of these animals. Importantly, this may shed light on mechanisms underlying both nonmotor and motor symptoms in PD, and may facilitate translational research aimed at identifying biomarkers for PD, related to nonmotor symptoms.
